Anixa Biosciences, Inc.

    Jurisdiction
    United States
    LEI
    549300PW2C2QTAJL2D19
    ISIN
    US03528H1095 (ANIX)
    Sectors
    1. Healthcare
    2. Biotechnology

    Scores

    InsiderPie Expert Score
    50 / 100
    Even with peer group:
    50 / 100
    Fair value (Benjamin Graham formula)
    N/A
    Financial strength (Piotroski F-Value)
    2 / 9
    Fundamental strength relative to industry (Mohanram G-Value)
    1 / 7

    Profile

    Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. Read full profile

    Fundamentals

    Net revenue
    €0.00
    Gross margin
    0.0%
    EBIT
    -€10.23M
    EBIT margin
    0.0%
    Net income
    -€7.55M
    Net margin
    0.0%

    Statement period: - (published )

    Stock price

    Stock price loading... No stock price available Stock price provided by Lang & Schwarz Steigende Zinsen und niedrigere Bewertungen für Wachstumsaktien im Allgemeinen Eine Gewinnwarnung beim Konkurrenten Adyen signalisiert eine Abkühlung des europäischen Markts für Zahlungsdienstleistungen. Eine Gewinnwarnung von Wordline SA triggert einen massiven Kursverlust.

    Configure chart

    Adjust colors to be more accessible for red-green-colorblind users.
    Scale
    Moving average Display a moving average line on the chart.

    Dividends

    No dividend payouts

    Analyst ratings

    No analyst ratings available

    Insider Transactions

    Name Title Transaction Date Shares Price Value
    Titterton Lewis H jr N/A +10K $3.08 +$30.80K
    KUMAR AMIT Chief Executive Officer +5K $3.16 +$15.80K
    Baskies Arnold M N/A +5K $3.39 +$16.95K

    Investor transactions

    Name Shares Value Last change Change type
    Peter Brown 21K $61.41K +6.9K Buy

    Earnings Calls

    Add to watchlist

    Notifications